Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) traded up 20.9% on Thursday . The stock traded as high as C$0.29 and last traded at C$0.26. 1,333,171 shares were traded during mid-day trading, an increase of 93% from the average session volume of 689,390 shares. The stock had previously closed at C$0.22.
Hemostemix Price Performance
The stock has a 50-day moving average price of C$0.10 and a 200-day moving average price of C$0.08. The company has a market capitalization of C$23.96 million, a P/E ratio of -13.75 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- 3 Best Fintech Stocks for a Portfolio Boost
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- Health Care Stocks Explained: Why You Might Want to Invest
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
